Travere Therapeutics, Inc. (TVTX): Depreciation & Amortization
$60.74M
Year ended 2025-12-31
$63.37M
Trailing 12 months to 2026-06-30
+43.1%
3-year compound annual growth
+19.8%
5-year compound annual growth
+16.3%
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $60.74M | +39.5% | 2026-02-19, From 2025-01-01 |
| 2024-12-31 | $43.55M | +13.0% | 2026-02-19, From 2024-01-01 |
| 2023-12-31 | $38.53M | +86.0% | 2026-02-19, From 2023-01-01 |
| 2022-12-31 | $20.72M | +62.6% | 2025-02-21, From 2022-01-01 |
| 2021-12-31 | $12.75M | -48.1% | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | $24.58M | +20.4% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $20.41M | +9.3% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $18.67M | +4.9% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $17.80M | +10.3% | 2020-02-24, From 2017-01-01 |
| 2016-12-31 | $16.14M | +20.5% | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | $13.39M | +148.0% | 2018-07-06, From 2015-01-01 |
| 2014-12-31 | $5.40M | n/m | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | $216.0K | +73.0% | 2016-02-26, From 2013-01-01 |
| 2012-12-31 | $124.9K | n/a | 2015-07-09, From 2012-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $60.74M | +39.5% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $13.84M | -2.6% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $5.43M | -10.6% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $24.24M | +2.6% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $15.01M | +26.6% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $13.31M | +7.8% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $15.27M | +12.1% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $3.06M | +48.3% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $91.63M | -6.7% |
Compare TVTX, NATR, BBIO, MIRM side by side · Screen every company in Pharmaceutical Preparations ↗